 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Do the Effects of Blood Pressure Drugs Differ by Kidney Function?
7 February 2006 | Volume 144 Issue 3 | Page I-33
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate." It is in the 7 February 2006 issue of Annals of Internal Medicine (volume 144, pages 172-180). The authors are M. Rahman, S. Pressel, B.R. Davis, C. Nwachuku, J.T. Wright Jr., P.K. Whelton, J. Barzilay, V. Batuman, J.H. Eckfeldt, M.A. Farber, S. Franklin, M. Henriquez, N. Kopyt, G.T. Louis, M. Saklayen, C. Stanford, C. Walworth, H. Ward, and T. Wiegmann, for the ALLHAT Collaborative Research Group.
What is the problem and what is known about it so far?
People with high blood pressure (BP) are more likely to develop heart, blood vessel, and kidney disease. Drugs that lower BP may prevent these complications. Drugs known as angiotensin-converting enzyme (ACE) inhibitors are thought to be best for preventing kidney failure in people with high BP and lower kidney function. Diuretics, also called water pills, are thought to be best for preventing cardiovascular disease (CVD) in people with high BP regardless of level of kidney function. How these and other BP drugs compare in their ability to prevent CVD and kidney failure has never been directly studied.
Why did the researchers do this particular study?
To compare the ability of different BP drugs to prevent CVD and kidney failure in people with high BP and different levels of kidney function.
Who was studied?
31,897 people with high BP and at least 1 other risk factor for CVD. All were 55 years of age or older.
How was the study done?
Participants were assigned at random to receive an ACE inhibitor, a water pill, or another type of BP-lowering drug known as a calcium-channel blocker. The researchers used a blood test to classify people as having normal, mildly reduced, or more severely reduced kidney function. They then compared the rates of CVD and kidney failure on the basis of participants' kidney function and the BP-lowering drug they were taking.
What did the researchers find?
Heart and blood vessel disease were more common than kidney failure in participants with reduced kidney function. The risk was highest for those with more severely reduced function. Overall, ACE inhibitors and water pills were about equally likely to protect against heart attacks. However, water pills seemed more effective at preventing some other kinds of CVD, stroke, and heart failure. Calcium-channel blockers and water pills were about equally likely to protect against all CVD. Water pills seemed more effective at preventing stroke. These results generally held for all participants regardless of kidney function.
What are the limitations of the study?
The researchers studied older people with at least 2 risk factors for CVD. The findings may not apply to younger people at lower risk. Participants were allowed to take BP-lowering drugs other than those the researchers directly studied. Also, they were not allowed to take more than 1 of the study drugs. Therefore, the findings may not apply to people taking a single BP-lowering drug or different combinations of drugs.
What are the implications of the study?
Cardiovascular disease is more common than kidney failure in older people with high BP and lower kidney function. The risk for CVD is highest in those with the lowest kidney function. Water pills were as effective as other drugs for preventing complications of CVD regardless of kidney function.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. T. Wright Jr, S. Harris-Haywood, S. Pressel, J. Barzilay, C. Baimbridge, C. J. Bareis, J. N. Basile, H. R. Black, R. Dart, A. K. Gupta, et al. Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, January 28, 2008; 168(2): 207 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Schneider, E. Ferrannini, R. DeFronzo, G. Schernthaner, J. Yates, and E. Erdmann Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Townsend Stroke in Chronic Kidney Disease: Prevention and Management Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S11 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saab, A. T. Whaley-Connell, R. Khanna, and J. R. Sowers Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 107 - 112. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Menon, M. G. Shlipak, X. Wang, J. Coresh, T. Greene, L. Stevens, J. W. Kusek, G. J. Beck, A. J. Collins, A. S. Levey, et al. Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease Ann Intern Med, July 3, 2007; 147(1): 19 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, T. H. Jafar, R. A. Hayward, H. Tighiouart, M. Landa, P. de Jong, D. de Zeeuw, G. Remuzzi, A.-L. Kamper, A. S. Levey, et al. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1959 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kottgen, S. D. Russell, L. R. Loehr, C. M. Crainiceanu, W. D. Rosamond, P. P. Chang, L. E. Chambless, and J. Coresh Reduced Kidney Function as a Risk Factor for Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Hayden, N. A. Chowdhury, S. A. Cooper, A. Whaley-Connell, J. Habibi, L. Witte, C. Wiedmeyer, C. M. Manrique, G. Lastra, C. Ferrario, et al. Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat Am J Physiol Renal Physiol, February 1, 2007; 292(2): F861 - F867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis, and M. Elisaf Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol. Dial. Transplant., January 1, 2007; 22(1): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guerrero, R. Montes, J. Munoz-Terol, A. Gil-Peralta, J. Toro, M. Naranjo, P. Gonzalez-Perez, C. Martin-Herrera, and A. Ruiz-Fernandez Peripheral arterial disease in patients with stages IV and V chronic renal failure Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3525 - 3531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.C. Edwards, R.P. Steeds, C.J. Ferro, and J.N. Townend The treatment of coronary artery disease in patients with chronic kidney disease QJM, November 1, 2006; 99(11): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Sawicki and N. McGauran Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care? Hypertension, July 1, 2006; 48(1): 1 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Levy Proteinuria, renal impairment, and death. BMJ, June 17, 2006; 332(7555): 1402 - 1403. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Malik JournalScan Heart, June 1, 2006; 92(6): 862 - 864. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Levey and K. Uhlig Which Antihypertensive Agents in Chronic Kidney Disease? Ann Intern Med, February 7, 2006; 144(3): 213 - 215. [Full Text] [PDF]
|
|
Read all Rapid Responses
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
